A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Haematologica

Volumn 93, Issue 8, 2008, Pages 1219-1226

  Liso, Arcangelo ^a   Castiglione, Filippo ^b   Cappuccio, Antonio ^b   Stracci, Fabrizio ^c   Schlenk, Richard F ^d   Amadori, Sergio ^e   Thiede, Christian ^f   Schnittger, Susanne ^g   Valk, Peter J M ^h   Döhner, Konstanze ^d   Martelli, Massimo F ^c   Schaich, Markus ^f   Krauter, Jürgen ⁱ   Ganser, Arnold ⁱ   Martelli, Maria P ^c   Bolli, Niccolò ^c   Löwenberg, Bob ^h   Haferlach, Torsten ^g   Ehninger, Gerhard ^f   Mandelli, Franco ^j   Döhner, Hartmut ^d   Michor, Franziska ^k   Falini, Brunangelo ^c   more..

^a UNIVERSITY OF FOGGIA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF ULM   (Germany)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ HANNOVER MEDICAL SCHOOL   (Germany)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Acute myeloid leukemia; Mutation; Nucleophosmin

Indexed keywords

NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CARCINOGENESIS; GENE MUTATION; INCIDENCE; LINEAR REGRESSION ANALYSIS; MATHEMATICAL MODEL; ONSET AGE;

ADULT; AGE OF ONSET; EUROPE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GERMANY; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MODELS, GENETIC; MODELS, THEORETICAL; MUTATION; NUCLEAR PROTEINS; REGISTRIES;

EID: 48749094968     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13209     Document Type: Article

References (47)

1. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
2. Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007;92:519-32.
3. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007;109:874-85.
4. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006;107:4514-23.
5. Quentmeier H, Martelli MP, Dirks WG, Bolli N, Liso A, Macleod RA, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia 2005;19:1760-7.
6. Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006;108:1999-2005.
7. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005;106:899-902.
8. Mullighan CG, Kennedy A, Zhou X, Radtke I, Phillips LA, Shurtleff SA, et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 2007;21:2000-9.
9. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008;105:3945-50.
10. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733-9.
11. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740-6.
12. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747-54.
13. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-20.
14. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776-84.
15. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-18.
16. Luebeck EG, Moolgavkar SH. Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci USA 2002;99:15095-100.
17. Vickers M. Estimation of the number of mutations necessary to cause chronic myeloid leukaemia from epidemiological data. Br J Haematol 1996;94:1-4.
18. Frank SA. Age-specific acceleration of cancer. Curr Biol 2004;14:242-6.
19. Frank SA. Age-specific incidence of inherited versus sporadic cancers: a test of the multistage theory of carcinogenesis. Proc Natl Acad Sci USA 2005;102:1071-5.
20. Michor F, Iwasa Y, Nowak MA. The age incidence of chronic myeloid leukemia can be explained by a one-mutation model. Proc Natl Acad Sci USA 2006;103:14931-4.
21. Vickers MA. JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation. Blood 2007;110:1675-80.
22. Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005;106:1419-22.
23. Moran P. The Statistical Processes of Evolutionary Theory. Oxford; 1962.
24. Abkowitz JL, Catlin SN, McCallie MT, Guttorp P. Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. Blood 2002;100:2665-7.
25. Skarberg KO. Cellularity and cell proliferation rates in human bone marrow. IV. Studies on bone marrow cellularity and erythrokinetics in hypoproliferative anaemia. Acta Med Scand 1974;195:313-7.
26. Mauer AM, Lampkin BC. Proceedings: Cellular kinetics in acute leukemia. Proc Natl Cancer Conf 1972;7:325-31.
27. Schessl C, Rawat VP, Cusan M, Deshpande A, Kohl TM, Rosten PM, et al. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. J Clin Invest 2005;115:2159-68.
28. Kim HG, Kojima K, Swindle CS, Cotta CV, Huo Y, Reddy V, et al. FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia. Blood 2008;111:1567-74.
29. Gallagher R. Duelling mutations in normal karyotype AML. Blood 2005;106:3681-2.
30. Jeong EG, Lee SH, Yoo NJ. Absence of nucleophosmin 1 (NPM1) gene mutations in common solid cancers. Apmis 2007;115:341-6.
31. Liso A, Bogliolo A, Freschi V, Martelli MP, Pileri SA, Santodirocco M, et al. In human genome, generation of a nuclear export signal through duplication appears unique to nucleophosmin (NPM1) mutations and is restricted to AML. Leukemia 2008. (Epub)
32. Shiseki M, Kitagawa Y, Wang YH, Yoshinaga K, Kondo T, Kuroiwa H, et al. Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Leuk Lymphoma 2007;48:2141-4.
33. Pasqualucci L, Li S, Meloni G, Schnittger S, Gattenlohner S, Liso A, et al. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? Leukemia 2008. (Epub)
34. Falini B. Any role for the nucleophosmin (NPM1) gene in myelodysplastic syndromes and acute myeloid leukemia with chromosome 5 abnormalities? Leuk Lymphoma 2007;48:2093-95.
35. Albiero E, Madeo D, Bolli N, Giaretta I, Bona ED, Martelli MF, et al. Identification and functional characterization of a cytoplasmic nucleophosmin leukaemic mutant generated by a novel exon-11 NPM1 mutation. Leukemia 2007;21:1099-103.
36. Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R, et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 2007;67:6230-7.
37. Falini B, Albiero E, Bolli N, De Marco MF, Madeo D, Martelli M, et al. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia 2007;21:2052-4.
38. Falini B, Mecucci C, Saglio G, Lo Coco F, Diverio D, Brown P, et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 2008;93:439-42.
39. Chou WC, Tang JL, Lin LI, Yao M, Tsay W, Chen CY, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006;66:3310-6.
40. Falini B, Martelli MP, Mecucci C, Liso A, Bolli N, Bigerna B, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008;93:775-9.
41. Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G, et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006;20:1103-8.
42. Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY, et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007;21:998-1004.
43. Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004;80-97.
44. Cheng K, Grisendi S, Clohessy JG, Majid S, Bernardi R, Sportoletti P, et al. The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. Oncogene 2007;26:7391-400.
45. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005;437:147-53.
46. Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008;111:3859-62.
47. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006;6:493-505.